Neurology | Home | MIMS Malaysia

Real-world study stamps seal of safety on dabigatran

Pearl Toh, an hour ago

Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.

Open surgery bests radiosurgery in mesial temporal lobe epilepsy

22 hours ago

Anterior temporal lobectomy appears to be more effective than the minimally invasive stereotactic radiosurgery in terms of inducing seizure remission in patients with pharmacoresistant unilateral mesial temporal lobe epilepsy, according to the results of the ROSE trial.

Add-on perampanel safe, effective in patients with secondarily generalized seizures

Yesterday

Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Statin-induced reduction in LDL lowers stroke, transient ischaemic attack risk

5 days ago

The composite risk of stroke and transient ischaemic attack appears to be reduced in the low-density lipoprotein (LDL) cholesterol level of 80–100 mg/dL, according to the posthoc analysis of the J-STARS (Japan Statin Treatment Against Recurrent Stroke) study.

High uric acid levels tied to increased dementia risk

Audrey Abella, 6 days ago

High levels of serum uric acid (SUA) in elderly people were associated with an increased risk of incident dementia, particularly vascular or mixed dementia, according to the Three City-Dijon study.

Management of dementia beyond cognition – a deeper look into BPSD and CVD

13 Dec 2017

At the Schwabe-Menarini lunch symposium of the 11^th International Congress of the Asian Society AgainstDementia (ASAD) 2017 held in Bangkok, Thailand, Professor Ralf Ihl highlighted the role of standardized Gingko biloba extract EGb 761^®for the treatment of patients with behavioural and psychological symptoms of dementia (BPSD). Meanwhile, Associate Professor Nagaendran Kandiah presented clinical findings on the association between cerebrovascular disease (CVD) and dementia, and emphasized the role of EGb 761^®in the management of dementia with CVD.

Drug and non-drug approaches to managing tension-type headache

01 Jul 2017

At the recent launch of Nurofen^® Express by Reckitt Benckiser Malaysia, Ms Joyce McSwan spoke on the importance of managing tension-type headache (TTH), highlighting the roles of drug and non-drug approaches in improving treatment outcomes.

Hypertension and cholesterol lowering interventions do not reduce cognitive decline

Roshini Claire Anthony, 22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

An uncommon cause of hyperthyroidism

Dr. Rose Zhao-Wei Ting, 16 Nov 2016

A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.

Excerpts from the Inaugural Meeting of the Dementia Advisory Board Malaysia

29 Apr 2016

This article presents the excerpts from the Inaugural Meeting of the Dementia Advisory Board Malaysia held on 23 January 2016 in Kuala Lumpur, highlighting the clinical evidence of Ginkgo biloba extract EGb761^®in dementia, treatment recommendations from international guidelines and consensus reached during the meeting on the role of EGb761^® in managing dementia.

First-line treatment with lanreotide for metastatic neuroendocrine tumours

03 Mar 2016

The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Time is still brain, say experts

Elvira Manzano, 21 Feb 2018

The treatment window for endovascular thrombectomy has been extended from 6 to 24 hours within the onset of a stroke in the new stroke guidelines, expanding the number of patients eligible for thrombectomy. However, experts said this does not mean time no longer matters in thrombectomy.

Low uptake of stroke testing following retinal infarction

Roshini Claire Anthony, 21 Feb 2018

Despite guidelines advocating stroke risk factor assessment following retinal infarction (stroke of the eye), adherence to the guidelines within 90 days of infarct was poor among elderly patients, leading to a potentially elevated risk of stroke, according to a study presented at the recent International Stroke Conference 2018 (ISC 2018) in Los Angeles, California, US.

Ticagrelor/aspirin combo reduces HOPR rate after minor stroke or TIA

Roshini Claire Anthony, 20 Feb 2018

The use of a ticagrelor/aspirin combination was more successful than a clopidogrel/aspirin combination in reducing the rate of high on-treatment platelet reactivity (HOPR) in patients with a recent minor stroke or transient ischaemic attack (TIA), according to results of the PRINCE* trial conducted in China.

EXTEND-IA TNK demonstrates superiority of tenecteplase over alteplase for prethrombectomy reperfusion

Roshini Claire Anthony, 09 Feb 2018

The use of tenecteplase may be a suitable alternative to alteplase prior to endovascular thrombectomy in patients with a large vessel ischaemic stroke, according to results of the EXTEND-IA TNK* study.

Candesartan/hydrochlorothiazide/rosuvastatin combo reduces stroke risk in patients with intermediate CV risk

Roshini Claire Anthony, 07 Feb 2018

A combination of the cholesterol-lowering drug rosuvastatin and blood pressure-lowering drugs candesartan and hydrochlorothiazide led to a significant 44 percent reduction in the risk of first strokes among individuals with an intermediate risk of cardiovascular (CV) disease, results from the HOPE-3* study showed.